Prospective examination of clinical efficacy of alendronate which is administrated prophylactically in glucocorticoid-induced osteoporosis

Not Applicable

• Conditions: glucocorticoid-induced osteoporosis

• Registration Number: JPRN-UMIN000002551
• Lead Sponsor: Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-09-27
• Study Completion: 2011-08-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1)Woman who hopes for pregnancy 2)Patient who has serious hepatopathy, renal damage, and cardiac disease 3)Patient who has received administering medicine that influences bone metabolism Medicine made of patient protein assimilation steroid(Winstrol, Primobolan, and Miotoron, etc.), Calcitonin(Elcitonin, Calcitriol, and Salmotonin, etc.), Ipriflavone(osten), vitamin K2(Glakey), androgenic hormone (TESTINON etc.), and female hormone (PREMARIN etc.), Raloxifene(Evista). However, after taking the medicine is stopped for eight weeks, it is possible to register. Patient who has received administering bisphosphonate. However, after taking the bisphosphonate is stopped for six months, it is possible to register. 4)Patient who judged it is improper to participation of physician in charge in clinical trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified